Characterization of Phenotypic and Genotypic Regressors for Imaging
- Conditions
- Healthy VolunteersSubstance Use Disorders
- Registration Number
- NCT01148381
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The influence of genes on addictive and neuropsychiatric disorders is complex, especially given that multiple genes likely influence certain behaviors that are correlated with addiction. Researchers are interested in looking at the genetic information of individuals who are enrolled on National Institute for Drug Abuse studies to investigate specific genetic variants that may be related to substance abuse. Researchers will study the effects of genes on several aspects of thinking such as attention, memory, decision making, problem solving, learning, and emotional feelings, and investigate the ways in which genetic information affects addictive behaviors and substance abuse. In addition, researchers will study how genes may explain differences in imaging data in substance users.
Objectives:
- To collect genetic information for research on genetic aspects of addiction and substance abuse.
Eligibility:
* Adults age 18 or older
* (1) healthy, non-drug-using nonsmokers,
* (2) healthy smokers,
* (3) healthy individuals dependent on other commonly abused drugs, and
* (4) individuals with other psychiatric disorders.
* Participants must be enrolled in another National Institute on Drug Abuse, Intramural Research Program imaging protocol.
Design:
* This study involves one to two visits to National Institute on Drug Abuse, Intramural Research Program that may be separate from the participant's current research protocol study visits or on the same day as those visits.
* Participants will provide a blood sample and complete questionnaires about mood, memory, and learning.
* Participants may also be asked to do a few tasks, such as playing computer games involving coin tosses and money management, or responding to questions on a computer screen....
- Detailed Description
Objective: To determine genetic variants as well as behavioral measures across different study group populations. Results of these will be used as regressors to help explain inter-individual differences in data collected across IRP protocols.
Study Population: The study population will include 1) healthy non-smoking, participants with no substance use disorders 2) healthy individuals with nicotine use disorder 3) healthy individuals with other substance use disorders 4) individuals with other psychiatric disorders and 5) treatment-seeking individuals with substance use disorders. Participants must be under evaluation for another NIDA-IRP protocol, generally healthy, and age 18 or older.
Design: The main study will require approximately 5-8 hours. Main study procedures may be done in 1 visit or multiple visits, and may be done in conjunction with another NIDA-IRP study. After being consented into the main study, the participant will be asked to submit a blood sample, an MRI scan, complete various questionnaires, characterization instruments and several behavioral tasks. Blood will only be drawn once, provided there are no technical problems (such as sample damage during collection, preparation, shipping or assay) requiring a repeat draw. If participants enroll in other NIDA-IRP imaging protocols, they will be asked to repeat a few of the time- sensitive questionnaires in this protocol during the MRI visits of the other protocols. Data acquired in this protocol will be compared to data acquired in other NIDA-IRP protocols.
An arm of this protocol will be used to pilot test a phenotyping battery developed by the NIDA CTN. This battery overlaps with several of the assessments in the main protocol. Participants in the NIDA CTN pilot study who also meet criteria for the main study may participate in the main study as well. The CTN Pilot procedures require approximately 4-6 hours to complete.
Outcome Measures: The primary outcome measures in this study are the genetic, behavioral and phenotypic factors that are related to addiction. Secondary outcome measures are to compare the genetic, behavioral and phenotypic factors to imaging and behavioral data acquired across other IRP protocols.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2625
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome measures are the genetic, behavioral and phenotypic factors that are related to addiction. each visit To determine whether genetic polymorphisms, phenotypic measures and behavioral characterization instruments can explain variance in structural and functional imaging data and in behavioral outcome measures such as treatment outcome or substance use trajectories or patterns as collected under other NIDA IRP protocols and clinical trials conducted in the NIDA CTN.
- Secondary Outcome Measures
Name Time Method Secondary outcome measures are to compare the genetic, behavioral and phenotypic factors to imaging and behavioral data acquired across other IRP protocols. each visit To compare the genetic, behavioral and phenotypic factors to imaging and behavioral data acquired across other IRP protocols
Trial Locations
- Locations (1)
National Institute on Drug Abuse, Biomedical Research Center (BRC)
🇺🇸Baltimore, Maryland, United States